Latham Advises OrganOx on US$142 Million Equity Financing

Latham & Watkins has advised OrganOx Ltd., a leading organ medical technology company, on its US$142 million primary and secondary equity financing. The additional funds will be used by OrganOx to accelerate growth opportunities for its metra^® platform technology in the large and high growth organ technology global market.

The round was led by new investor HealthQuest Capital with support from existing OrganOx investors BGF and Lauxera Capital Partners, along with additional new investors Sofina, Soleus Capital, and Avidity Partners. Existing OrganOx investors include the University of Oxford, Technikos, the Oxford Technology and Innovations Fund, and Longwall Ventures.

The Latham team was led by London partner Shing Lo and Orange County/Bay Area partner Ross McAloon, with London associates Samantha Peacock, Oscar Ko, Darragh Hyland, and Victoria Mah, and New York associate Eduard Grigoryan. Advice was also provided on UK employee matters by London partner Kendall Burnett, with associate Rebecca Servian; on US employee matters by Bay Area partner Maj Vaseghi; and on tax matters by London partners Karl Mah and Sean Finn, with associate Abi Abbott.